Rivastigmine Mini-Tablet for Alzheimer's Disease
ConditionAlzheimer's Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorPeking University First Hospital
About this trial
The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).
Eligibility criteria
Qualifiers
Age 50 or older
Meet the National Institute of Aging-Alzheimer's Association clinical criteria for probable Alzheimer's disease
Have a Mini-Mental State Examination score of 10 to 24 at Screening and Baseline
Geriatric Depression Scale score <=7 at Screening
Disqualifiers
Any systemic or neurological condition that could contribute to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease
Any psychiatric diagnosis or symptoms (hallucinations, major depression, delusions, etc) interfering with study procedures
An advanced, severe or unstable disease of any type (cardiac, respiratory, gastrointestinal, renal disease, etc) that may interfere with efficacy evaluations
Subjects treated with medication for dementia two weeks prior to baseline
Trial design
Treatments tested in this trial
- Rivastigmine Mini-Tablet
- Donepezil Hydrochloride
Treatment groups
1,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov